PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Cost reduction while AXSM shows 42.03% growth. Joel Greenblatt would examine competitive advantage.
4.31%
Gross profit growth below 50% of AXSM's 21.76%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth less than half of AXSM's 39.77%. David Dodd would verify if efficiency advantage is sustainable.
-40.17%
G&A reduction while AXSM shows 5.46% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while AXSM shows 12.14% growth. Joel Greenblatt would examine advantage.
-8.25%
Total costs reduction while AXSM shows 13.44% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Both companies reducing D&A. Martin Whitman would check industry patterns.
8.31%
EBITDA growth exceeding 1.5x AXSM's 4.03%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth exceeding 1.5x AXSM's 4.51%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Other expenses growth above 1.5x AXSM's 72.27%. Michael Burry would check for concerning trends.
12.55%
Pre-tax income growth exceeding 1.5x AXSM's 7.24%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Similar tax expense growth to AXSM's 209.89%. Walter Schloss would investigate patterns.
12.55%
Net income growth exceeding 1.5x AXSM's 7.40%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
15.52%
Similar EPS growth to AXSM's 14.29%. Walter Schloss would investigate industry trends.
15.52%
Similar diluted EPS growth to AXSM's 14.29%. Walter Schloss would investigate industry trends.
3.21%
Share count reduction exceeding 1.5x AXSM's 7.89%. David Dodd would verify capital allocation.
3.21%
Diluted share reduction exceeding 1.5x AXSM's 7.89%. David Dodd would verify capital allocation.